The number of ovarian cystadenoma of low potential malignancy (abbreviation: LPM) was 31 (5.7%) among common epithelial tumors [benign cystadenoma = 400 (74.0%), carcinoma = 110 (20.3%)]. Their mean ages, bilaterlity, frequency of ascites and nulligravidity were situated intermediately between those of benign cystadenoma and carcinoma. Abdominal tumor, distention, pain and metromenorrhagia were the main symptoms, although gastrointestinal complaints were rare in LPM cystadenoma. With LPM cystadenoma, 19 (61.3%) patients were at stage I, 7 (22.6%) at stage II and 5 (16.1%) at stage III, but with carcinoma, 44 (40.0%) were at stage III-IV [33 (30.0%) at stage I, and 31 (28.2%) at stage II]. The 5-year actuarial survival rate was 90% for LPM cystadenoma, but 43% for carcinoma. These results suggest that the clinical and biological features as well as the histological definition of LPM cystadenoma are situated intermediately between those of benign cystadenoma and carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1447-0756.1991.tb00032.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atypical proliferating mucinous tumors of gigantic dimensions.
Vojnosanit Pregl
December 2008
Institute of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade.
Unlabelled: BACKGROUND; Ovarian tumors of low malignant potential (LMP) are also known as atypically proliferating tumors. Ovarian tumors of LPM account for approximately 15% of all epithelial ovarian cancers. Mean age of occurrence is 40 years and they are 15-20 cm in diameter.
View Article and Find Full Text PDFClinicostatistical study of low potential malignancy ovarian cystadenoma (borderline cases).
Asia Oceania J Obstet Gynaecol
June 1991
Division of Gynecology, Saitama Cancer Center, Japan.
The number of ovarian cystadenoma of low potential malignancy (abbreviation: LPM) was 31 (5.7%) among common epithelial tumors [benign cystadenoma = 400 (74.0%), carcinoma = 110 (20.
View Article and Find Full Text PDFAntitumor activity of cisplatin analogs against malignant ovarian tumor xenografts into nude mice.
Nihon Sanka Fujinka Gakkai Zasshi
November 1988
Department of Obstetrics and Gynecology, Kurume University School of Medicine.
The antitumor activity of new platinum analogs was studied at equitoxic doses to that of cisplatin (CDDP) in BALB/C nu-nu nude mice bearing xenografts of human ovarian malignant tumors. The following two tumor lines were used: OH-1 (serous cystadenocarcinoma) and MP-1 (mucinous cystadenoma, LPM). 1) Antitumor activity was determined for all agents from the T/C ratio for OH-1.
View Article and Find Full Text PDFCommon epithelial tumors of the ovary, which were found during the preclinical stage in the 5 cases were described, and the histogenesis of ovarian tumors was discussed. 1. All the ovaries in the 5 cases maintained a nearly normal external appearance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!